Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Appendix B: Panel Roster and Financial Disclosures


Last Updated: January 1, 2020; Last Reviewed: August 1, 2019

Progressive Multifocal Leukoencephalopathy
Member Financial Disclosure
Company Relationship
Agnihotri, Shruti University of Alabama at Birmingham None N/A
Cinque, Paola San Raffaele Scientific Institute, Milan, Italy Gilead Research Support
Janssen Consultant
Pfizer Data Safety Monitoring Board
Shire Data Safety Monitoring Board
Clifford, David* Washington University School of Medicine Atara Consultant
Biogen Idec Consultant
Bristol-Myers Squibb Consultant
Dr. Reddy’s Laboratories Inc. Consultant
EMD Serono Consultant
Genentech Data Safety Monitoring Board
Genzyme Data Safety Monitoring Board
GlaxoSmithKline Consultant
Hoffmann LaRoche Data Safety Monitoring Board
Inhibikase Therapeutics Consultant
Merck Data Safety Monitoring Board
Mitsubishi Tanabe Pharmaceuticals Consultant
Pfizer Consultant
Quintiles Data Safety Monitoring Board
Shire Data Safety Monitoring Board
Takeda Data Safety Monitoring Board
Wave Life Sciences Data Safety Monitoring Board
Marra, Christina University of Washington School of Medicine International NeuroHIV Cure Consortium Consultant
Johnson & Johnson Equity Interest
McKesson Equity Interest
NIH Research Support
UpToDate Royalties
Wolters Kluwer Royalties
Miro, Jose M. Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain None N/A
Nath, Avindra National Institutes of Health None N/A
* Group lead

Note: Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.

Download Guidelines